TSX:DHT.UN - Post by User
Post by
SuperMon Oct 01, 2021 2:08pm
274 Views
Post# 33953242
From Globe & Mail this AM
From Globe & Mail this AM * With the announcement of its acquisition of royalties on Oracea (doxycycline) for US$46.4-million as well as a share buyback program, RBC Dominion Securities analyst Douglas Miehm increased his DRI Healthcare Trust (
) target by $1 to $16, keeping an “outperform” rating. The average is $14.42.
“We believe the shares are materially undervalued at 0.6 times our NAV,” said Mr. Miehm.
Small volume on this stock, but based on upside scenario, I took a small position today. GLTA